Showing 71 - 80 of 643
Using Dutch data we empirically investigate how financing and innovation vary across firm characteristics. We find that … when firms face financial constraints, debt financing and innovation choices are not independent of firm characteristics …
Persistent link: https://www.econbiz.de/10010249680
promotion. In this paper, we assess one popular justification for feed-in tariffs, i.e., induced innovation as a positive … spillover externality. Based on regressions with a time-technology fixed effect negative binomial model, we find that innovation …
Persistent link: https://www.econbiz.de/10010252146
Persistent link: https://www.econbiz.de/10011523893
Persistent link: https://www.econbiz.de/10011524038
This paper examines how entrepreneurs and incumbents differ in R&D strategies. We show that entrepreneurs have incentives to choose projects with higher risk and a higher potential in order to reduce expected commercialization costs. However, entrepreneurs may still select too safe projects from...
Persistent link: https://www.econbiz.de/10011549385
workers contribute positively. We propose a theoretical model, highlighting the relationship between demographics, innovation …
Persistent link: https://www.econbiz.de/10011457979
Persistent link: https://www.econbiz.de/10011487058
This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of …. Domestic innovation is measured as citation-weighted domestic patents filed at the European Patent Office (EPO): to account for … to patent at the EPO. Results show that, in the short-run, IPR stimulate innovation. The effect for developing countries …
Persistent link: https://www.econbiz.de/10011509446
gains taxation, innovation subsidies, public R&D spending and other policy initiatives. …
Persistent link: https://www.econbiz.de/10011511054
Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months) - about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …
Persistent link: https://www.econbiz.de/10010473542